1. At a Glance
Shalby Ltd, aka India’s unofficial “Joint Replacement Factory,” is limping around with a ₹2,668 Cr market cap and a CMP of ₹247. On the hospital beds side, it flaunts 2,350+ beds across 11 hospitals and 5 orthopedic centers, plus 60 domestic clinics and 23 abroad. On the implants side, it produces 80,000+ knee/hip components annually, with ambitions of becoming a $100 Mn implants business. Yet, the stock market isn’t impressed—profits fell into negative territory in FY25 (PAT: -₹0.52 Cr), while debt has swollen to ₹476 Cr (from ₹155 Cr in FY22). Operating margins are stuck at 12%, occupancy is at a depressing 48%, and ROE is only 0.62%—basically, they’ve replaced more knees than they’ve created shareholder value.
2. Introduction
Welcome to Shalby Ltd, where patients walk out with new knees but investors limp out with old returns. Founded by Dr. Vikram Shah (India’s “knee replacement king”), the company proudly claims to be the global leader in knee replacements—150,000+ joints replaced so far. Imagine the world’s largest orthopedic wedding baraat, except the groom is debt and the bride is negative PAT.
Shalby runs a mix of hospitals, orthopedic centers, implant manufacturing, and asset-light franchises. That sounds like a diversified healthcare empire, but in reality, it’s like juggling multiple scalpels while standing on a rolling hospital bed. Between FY22 and FY24, healthcare services revenue grew 28%, implants business grew 150%, and yet net profit has trended downward. Basically: revenue marathon, profit heart attack.
And here’s the real kicker—they made headlines in July 2025 for performing the world’s first fully autonomous robotic joint replacement surgery. While that’s great for medicine, for investors it’s like Tesla launching a new car while its own stock battery is flat.
Question: If Shalby can make robots operate knees, why can’t it make its balance sheet walk straight?
3. Business Model – WTF Do They Even Do?
- Hospitals (90% revenue in H1 FY25):
11 multi-specialty tertiary hospitals + 5 ortho centers = 2,350 beds. Covers 30+ specializations from arthroplasty to oncology.
- Metrics: Occupancy stuck at ~48%, ARPOB rising (₹41,072 in H1 FY25 vs ₹31,347 in FY22).
- Patient count? Falling. Surgeries dropped from 30,031 in FY24 to 16,529 in H1 FY25. So basically, less cutting = less cash.
- Implants (10% revenue in H1 FY25 vs 4% in FY22):
Produced in California via Shalby Advanced Tech Inc. Exported to USA, Japan, Indonesia.
- Current: 4,600 units/month capacity.
- Ambition: $100 Mn implants business (i.e., become the “Apple of knees”).
- Franchise Model (SOCE):
Asset-light centers under “Shalby Orthopedics Centre of Excellence.” Two models:
- FOSO: Franchise Owned, Shalby Operated.
- FOSM: Franchise Owned, Shalby Managed.
Four units launched, target 40 units in 3–4 years.
- Acquisitions:
- Sanar International Hospital (87% stake, ₹102 Cr): 130 beds in Gurugram, 70% of revenue from international patients.
- Healers Hospital Pvt Ltd (₹104 Cr): To strengthen Sanar.
So yes, they’re everywhere—from Gujarat knees to Gurugram livers to US hip implants.
